HypoPrevent Toolkit

Purpose

The HypoPrevent Toolkit is an exclusive resource for participating practices that contains provider and patient resources that are: an evidence-based, easily accessible, supportive of practice-based quality improvement, and aligned with the goals of the Hypoglycemia Prevention Initiative. The Toolkit provides both quality and clinical resources for members of the practice to use in implementing the intervention at every stage of the clinical workflow, in addition to providing resources aimed at patients and helping them better understand and manage their hypoglycemia risk.


Audience

Access to the HypoPrevent Toolkit is given to participating providers. However, there are patient resources in the Toolkit that the provider can share with patients at his or her discretion.


The HypoPrevent Toolkit has been designed with the clinical workflow in mind. Following screening for at-risk patients, the provider will conduct an assessment and develop a care plan. At this time, the provider can chose to share any patient educational resources to aid the patient. Each workflow segment is categorized further by topic. Topics and resources are then organized by Alpha order. Additional resources are included in the Toolkit that may not be used during point-of-care, but are integral resources. This includes guidelines, reference journal articles, and supplemental resources for patient assessments.


Patient Educational Resources

These resources are intended for patients, as the provider sees appropriate. The resources are organized by topic and scored for literacy level. The SMOG Index is used - which computes readability based on the number of syllables per word. The number indicates the reading level of each resource. The higher the score, the higher the reading level. For more information, review the scoring instructions.

HypoPrevent Study Workflow
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.